YHDF Drug
Phase 1Small molecule
Novo NordiskYHDF Drug is one of 32 small molecule programs targeting Pneumonia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
155 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Plaquenil
Jazz PharmaceuticalsPreclinical
Innohep
Jazz PharmaceuticalsPreclinical
Zantac 150
CChattem
Preclinical
Retrovir
BBp Consulting, Inc
Preclinical
Primsol
CConrado Roberto Hoffmann Filho
Preclinical
Mucinex
RReckitt Benckiser LLC
Preclinical
Cancidas
FFresenius Kabi Taiwan Ltd.
Preclinical
Salbutamol
GSKPreclinical
Gantanol
CConrado Roberto Hoffmann Filho
Preclinical
Combination Therapy
Chong Kun Dang PharmaceuticalPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pneumonia1 trial
A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli
Not yet recruiting·—·Phase 1·NCT07338123·240 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YHDF Drug. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company